Needham analyst Alan Carr assigned a Buy rating to SCYNEXIS (SCYX) today and set a price target of $5.00. The company’s shares closed last Tuesday at $0.92.
According to TipRanks.com, Carr is a 1-star analyst with an average return of -3.1% and a 39.0% success rate. Carr covers the Healthcare sector, focusing on stocks such as Lexicon Pharmaceuticals, Phathom Pharmaceuticals, and ACADIA Pharmaceuticals.
Currently, the analyst consensus on SCYNEXIS is a Strong Buy with an average price target of $4.38.
See today’s analyst top recommended stocks >>
Based on SCYNEXIS’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $14.46 million. In comparison, last year the company earned revenue of $64K and had a net profit of $1.94 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
